Summary:

Lucid Diagnostics is a highly differentiated, medical device innovator with products designed to diagnose and treat conditions of the esophagus, including conditions arising from chronic heartburn which may lead to esophageal cancer.

Lucid Diagnostics is developing a revolutionary technology such as a non-invasive, office-based targeted cell collection device (EsoCheck) and a lab-based, DNA biomarker test (EsoGuard) to detect the precursor condition (Barrett’s Esophagus or BE) to highly lethal esophageal cancer.

Moving a medical device from discovery to regulatory review takes years of research, data analysis and paperwork. EsoCheck, a new screening method for Barrett’s esophagus (BE) detection, made it through thanks to the dedication of University Hospitals physicians and researchers.